Delayed neutrophil engraftment in cord blood transplantation with intensive administration of mycophenolate mofetil for GVHD prophylaxis

Bone Marrow Transplantation

Volumn 46, Issue 1, 2011, Pages 148-149

  Okamura, A ^a   Shimoyama, M ^a   Ishii, S ^a   Wakahashi, K ^a   Asada, N ^a   Kawano, H ^a   Kawamori, Y ^a   Nishikawa, S ^a   Minagawa, K ^a   Katayama, Y ^a   Matsui, T ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG EFFICACY; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LETTER; MALE; NEUTROPHIL; PRIORITY JOURNAL; RATING SCALE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; BONE MARROW TRANSPLANTATION; CORD BLOOD STEM CELL TRANSPLANTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEUTROPHILS; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 78651350483     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.59     Document Type: Letter

References (9)

1. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 621-625.
2. Giaccone L, McCune JS, Maris MB, Gooley TA, Sandmaier BM, Slattery JT et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood 2005; 106: 4381-4388.
3. Okamura A, Yamamori M, Shimoyama M, Kawano Y, Kawano H, Kawamori Y et al. Pharmacokinetics-based optimal doseexploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation. Int J Hematol 2008; 88: 104-110.
4. Royer B, Larosa F, Legrand F, Gerritsen-van Schieveen P, Berard M, Kantelip JP et al. Pharmacokinetics of mycophenolic acid administered 3 times daily after hematopoietic stem cell transplantation with reduced-intensity regimen. Biol Blood Marrow Transplant 2009; 15: 1134-1139.
5. Nishikawa S, Okamura A, Yamamori M, Minagawa K, Kawamori Y, Kawano H et al. Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease. Transplant Proc 2009; 41: 3873-3876.
6. Pidala J, Kim J, Perkins J, Field T, Fernandez H, Perez L et al. Mycophenolate mofetil for the management of steroidrefractory acute graft vs host disease. Bone Marrow Transplant 2010; 45: 919-924.
7. Cuomo G, Abignano G, Valentini G. Early onset neutropenia after mycophenolate mofetil in systemic sclerosis. Rheumatol Int 2009; 29: 1529-1530.
8. Miljkovic D, Cvetkovic I, Stosic-Grujicic S, Trajkovic V. Mycophenolic acid inhibits activation of inducible nitric oxide synthase in rodent fibroblasts. Clin Exp Immunol 2003; 132: 239-246.
9. Shimizu H, Takahashi M, Takeda S, Inoue S, Fujishiro J, Hakamata Y et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 2004; 77: 1661-1667.